Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247818 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of PH-10 for Psoriasis
A Phase 2 study of Psoriasis, sponsored by Provectus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 4
- Study locations
NCT01247818: Completed Phase 2 study of Psoriasis, sponsored by Provectus Pharmaceuticals.
NCT01247818 is a Phase 2 study of Psoriasis that has completed, run by Provectus Pharmaceuticals. The registered enrollment target is 99 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01247818, a Phase 2 study of Psoriasis, has completed, sponsored by Provectus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 4
- Study locations
Study Summary
PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This multicenter phase 2 study of subjects randomized sequentially by center to one of four treatment cohorts will assess efficacy and safety of topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG PH-10 (0.002% Rose Bengal)
- DRUG PH-10 (0.005% Rose Bengal)
- DRUG PH-10 (0.01% Rose Bengal)
Study Locations (4)
California
- Dermatology Specialists, Inc. - Oceanside
Florida
- International Dermatology Research - Miami
New York
- Mount Sinai School of Medicine - New York
North Carolina
- Wake Research Associates - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT01247818 record still lists
NCT01247818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT01247818 reports a single indexed study location in California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01247818 about?
NCT01247818 is a clinical study titled "Randomized Study of PH-10 for Psoriasis". PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This multicenter phase 2 study of subjects randomized sequentially by center...
What is the current status of trial NCT01247818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2010-12. Estimated completion is 2012-03.
What conditions does trial NCT01247818 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01247818?
The interventions under investigation include: Vehicle (DRUG), PH-10 (0.002% Rose Bengal) (DRUG), PH-10 (0.005% Rose Bengal) (DRUG), PH-10 (0.01% Rose Bengal) (DRUG).
Who is sponsoring clinical trial NCT01247818?
This trial is sponsored by Provectus Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01247818 being conducted?
This trial has 4 study locations across California, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01247818's enrollment target sits among peer trials
99 59th of 125 higher than 67 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia